LLY · News · 20260907N

Product / Drug Pipeline Progress - Lp(a)

ELI LILLY & Co · 2026-09-07 · Importance 5 · Surprise 24

Novartis and Ionis Pharmaceuticals’ Phase 3 pelacarsen trial failed to reduce heart attacks and strokes, despite lowering lipoprotein(a) levels. The result raises uncertainty for the emerging Lp(a)-targeted cardiovascular drug class and could affect development expectations for Eli Lilly’s comparable therapies. Detailed trial results are expected at an upcoming medical meeting, which may influence Lilly’s cardiovascular pipeline strategy and investment outlook.

Key facts

• Novartis's experimental cholesterol drug pelacarsen failed to reduce heart attack and stroke risk in a late-stage study, a setback that "raises questions for rival companies Amgen and Eli Lilly developing similar treatments." source